G protein-coupled receptor kinase 2 promotes cardiac hypertrophy

The increase in protein activity and upregulation of G-protein coupled receptor kinase 2 (GRK2) is a hallmark of cardiac stress and heart failure. Inhibition of GRK2 improved cardiac function and survival and diminished cardiac remodeling in various animal heart failure models. The aim of the present study was to investigate the effects of GRK2 on cardiac hypertrophy and dissect potential molecular mechanisms. In mice we observed increased GRK2 mRNA and protein levels following transverse aortic constriction (TAC). Conditional GRK2 knockout mice showed attenuated hypertrophic response with preserved ventricular geometry 6 weeks after TAC operation compared to wild-type animals. In isolated neonatal rat ventricular cardiac myocytes stimulation with angiotensin II and phenylephrine enhanced GRK2 expression leading to enhanced signaling via protein kinase B (PKB or Akt), consecutively inhibiting glycogen synthase kinase 3 beta (GSK3β), such promoting nuclear accumulation and activation of nuclear factor of activated T-cells (NFAT). Cardiac myocyte hypertrophy induced by in vitro GRK2 overexpression increased the cytosolic interaction of GRK2 and phosphoinositide 3-kinase γ (PI3Kγ). Moreover, inhibition of PI3Kγ as well as GRK2 knock down prevented Akt activation resulting in halted NFAT activity and reduced cardiac myocyte hypertrophy. Our data show that enhanced GRK2 expression triggers cardiac hypertrophy by GRK2-PI3Kγ mediated Akt phosphorylation and subsequent inactivation of GSK3β, resulting in enhanced NFAT activity.

[1]  D. Sorriento,et al.  Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac Hypertrophy , 2015, Journal of Cardiovascular Translational Research.

[2]  J. Moalem,et al.  Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression. , 2014, Journal of the American College of Cardiology.

[3]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  W. Koch,et al.  Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy , 2013, Front. Physiol..

[6]  U. Haberkorn,et al.  AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. , 2013, European heart journal.

[7]  W. Koch,et al.  Prodeath Signaling of G Protein–Coupled Receptor Kinase 2 in Cardiac Myocytes After Ischemic Stress Occurs Via Extracellular Signal–Regulated Kinase-Dependent Heat Shock Protein 90–Mediated Mitochondrial Targeting , 2013, Circulation research.

[8]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[9]  S. Houser,et al.  Cardiac G-Protein–Coupled Receptor Kinase 2 Ablation Induces a Novel Ca2+ Handling Phenotype Resistant to Adverse Alterations and Remodeling After Myocardial Infarction , 2012, Circulation.

[10]  H. Rockman,et al.  Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.

[11]  Mark A Sussman,et al.  Myocardial AKT: the omnipresent nexus. , 2011, Physiological reviews.

[12]  T. Matsui,et al.  Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. , 2011, Current pharmaceutical design.

[13]  G. Dorn,et al.  G Protein–Coupled Receptor Kinase 2 Activity Impairs Cardiac Glucose Uptake and Promotes Insulin Resistance After Myocardial Ischemia , 2011, Circulation.

[14]  F. von Wegner,et al.  The Inotropic Peptide &bgr;ARKct Improves &bgr;AR Responsiveness in Normal and Failing Cardiomyocytes Through G&bgr;&ggr;-Mediated L-Type Calcium Current Disinhibition , 2011, Circulation research.

[15]  David M. Harris,et al.  Level of G protein–Coupled Receptor Kinase-2 Determines Myocardial Ischemia/Reperfusion Injury via Pro- and Anti-Apoptotic Mechanisms , 2010, Circulation research.

[16]  Cristina Murga,et al.  The complex G protein‐coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets , 2010, British journal of pharmacology.

[17]  S. Houser,et al.  G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure , 2008, Circulation research.

[18]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[19]  I. Shiojima,et al.  Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.

[20]  G. Dorn,et al.  Cardiac-Specific Ablation of G-Protein Receptor Kinase 2 Redefines Its Roles in Heart Development and &bgr;-Adrenergic Signaling , 2006, Circulation research.

[21]  P. Penela,et al.  Mdm2 is involved in the ubiquitination and degradation of G‐protein‐coupled receptor kinase 2 , 2006, The EMBO journal.

[22]  T. Kozasa,et al.  Snapshot of Activated G Proteins at the Membrane: The Gαq-GRK2-Gßγ Complex , 2005, Science.

[23]  J. Molkentin,et al.  Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. , 2004, Biochemical and biophysical research communications.

[24]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[25]  M. Boerries,et al.  Extracellular S100A1 Protein Inhibits Apoptosis in Ventricular Cardiomyocytes via Activation of the Extracellular Signal-regulated Protein Kinase 1/2 (ERK1/2)* , 2003, Journal of Biological Chemistry.

[26]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[27]  R. Lefkowitz,et al.  Regulation of G protein-coupled receptor signaling by scaffold proteins. , 2002, Circulation research.

[28]  Robert J. Lefkowitz,et al.  Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors , 2001, Nature Reviews Neuroscience.

[29]  M. Caron,et al.  Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by β-Adrenergic Receptor Kinase 1 , 2001, The Journal of Biological Chemistry.

[30]  E. Lakatta,et al.  Erratum: Culture and adenoviral infection of adult mouse cardiac myocytes: Methods for cellular genetic physiology (American Journal of Physiology - Heart and Circulatory Physiology (July 2000) 279:48 (H429-H436)) , 2000 .

[31]  E. Lakatta,et al.  Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. , 2000, American journal of physiology. Heart and circulatory physiology.

[32]  R. Penn,et al.  Analysis of the human G protein-coupled receptor kinase 2 (GRK2) gene promoter: regulation by signal transduction systems in aortic smooth muscle cells. , 2000, Circulation.

[33]  W. Koch,et al.  Gβγ-dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy* , 2000, The Journal of Biological Chemistry.

[34]  W. Koch,et al.  Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. , 2000, The Journal of biological chemistry.

[35]  D. Levy,et al.  Why is left ventricular hypertrophy so predictive of morbidity and mortality? , 1999, The American journal of the medical sciences.

[36]  J. Ross,et al.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Lefkowitz,et al.  Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.

[38]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[39]  W. Koch,et al.  Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.

[40]  M. MacDonald,et al.  Characterization of the G Protein-coupled Receptor Kinase GRK4 , 1996, The Journal of Biological Chemistry.

[41]  R. Lefkowitz,et al.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.

[42]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[43]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.